Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Roudaut

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Value in Health

English

Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective

BMC Health Services Research

Health Policy

2015

English

Related publications

Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile

English

Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

English

Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands

English

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

English

Dapagliflozin (Forxiga®) Versus Glipizide as Add-On Therapies in Type 2 Diabetes Mellitus (T2dm); An Update of the Cost-Effectiveness Based on Long-Term Clinical Evidence From Uk NHS Perspective

English

Fournier’s Gangrene in a Patient on Dapagliflozin Treatment for Type 2 Diabetes

English

Dapagliflozin: A New Adjunct in the Treatment of Type 2 Diabetes Mellitus

International Journal of Basic & Clinical Pharmacology

2014

English

Intensive Insulin Therapy as the Primary Treatment for Type 2 Diabetes

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Roudaut

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective

Related publications

Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile

Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

Dapagliflozin (Forxiga®) Versus Glipizide as Add-On Therapies in Type 2 Diabetes Mellitus (T2dm); An Update of the Cost-Effectiveness Based on Long-Term Clinical Evidence From Uk NHS Perspective

Fournier’s Gangrene in a Patient on Dapagliflozin Treatment for Type 2 Diabetes

Dapagliflozin: A New Adjunct in the Treatment of Type 2 Diabetes Mellitus

Intensive Insulin Therapy as the Primary Treatment for Type 2 Diabetes